SCHEMBL23926384

SCHEMBL23926384

CN1CCN(CCc2cccc(C=O)c2O)CC1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 6/20 0.47
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 1/20 0.47
RAD52 P43351 1/20 0.47
KMT2A Q03164 1/20 0.47
HTR2A P28223 1/20 0.47
HTR2C P28335 1/20 0.47
HTR2B P41595 1/20 0.47
HRH3 Q9Y5N1 1/20 0.42
SIGMAR1 Q99720 5/20 0.41
KCNH2 Q12809 3/20 0.40
TLR2 O60603 1/20 0.40
TLR1 Q15399 1/20 0.40
TLR6 Q9Y2C9 1/20 0.40
KCNJ1 P48048 1/20 0.37
MC4R P32245 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23926362 0.88 HRH3 (0.55) ERN1HTR2AHTR2CHTR2BHRH3
SCHEMBL23926340 0.84 ERN1 (0.46) ERN1MEN1ALDH1A1KMT2AHRH3
SCHEMBL21002293 0.78 ERN1 (0.59) ERN1MEN1ALDH1A1KMT2ATLR2
SCHEMBL23926337 0.77 SIGMAR1 (0.48) ERN1MEN1ALDH1A1KMT2ASIGMAR1
SCHEMBL24127984 0.75 HTR2C (0.48) HTR2AHTR2CHTR2BHRH3SIGMAR1
SCHEMBL23964437 0.75 ALDH1A1 (0.50) ALDH1A1HTR2AHTR2CHTR2BHRH3
SCHEMBL1527632 0.75 ERN1 (0.52) ERN1MEN1KMT2ATLR2TLR1
SCHEMBL29953931 0.75 ERN1 (0.52) ERN1MEN1KMT2ATLR2TLR1
SCHEMBL3695408 0.74 ERN1 (0.52) ERN1MEN1ALDH1A1RAD52KMT2A
SCHEMBL14354373 0.73 ERN1 (0.53) ERN1MEN1ALDH1A1KMT2ATLR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4168408-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES Alterity Therapeutics Limited (AU) 2023-04-26 EP disclosed
CN-115667256-A Compounds for treating diseases and methods of treating diseases 艾特里提治疗有限公司 2023-01-31 CN disclosed
WO-2021253091-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES Alterity Therapeutics Limited (AU) 2021-12-23 WO disclosed
US-11155547-B1 Compounds for and methods of treating diseases Alterity Therapeutics Limited (AU) 2021-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11155547-B1 Compounds for and methods of treating diseases HTT, SNCA, PARK7 ERN1 3580/4885MEN1 1161/4885ALDH1A1 2721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.